Conivaptan: Potential Therapeutic Implications in Heart Failure

Title: Conivaptan: Potential Therapeutic Implications in Heart Failure

Volume: 3 Issue: 2

Author(s): Stephen Y. Chen, Zuheir Abrahams, George G. Sokos, Wilfried Mullens, Robert Hobbs, David O. Taylor and Gonzalo V. Gonzalez-Stawinski

Affiliation:

Keywords: Conivaptan, aquaretic, vasopressin receptor antagonists, congestive heart failure

Abstract: Conivaptan, a dual vasopressin receptor antagonist, is a member of an emerging class of medications for the treatment of euvolemic hyponatremia. These agents induce a free-water diuresis as compared to the natriuretic effect of loop diuretics and make them an intriguing prospect for the treatment of congestive heart failure. Article also includes recent patents on this topic.

Cite this article as:

Chen Y. Stephen, Abrahams Zuheir, Sokos G. George, Mullens Wilfried, Hobbs Robert, Taylor O. David and Gonzalez-Stawinski V. Gonzalo, Conivaptan: Potential Therapeutic Implications in Heart Failure, Recent Patents on Cardiovascular Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489008784705403

DOI https://dx.doi.org/10.2174/157489008784705403	Print ISSN 2212-3962
Publisher Name Bentham Science Publisher	Online ISSN 1574-8901